| Literature DB >> 35408849 |
Paola Zanetta1, Margherita Ormelli1, Angela Amoruso2, Marco Pane2, Barbara Azzimonti1, Diletta Francesca Squarzanti1.
Abstract
Oral lichen planus (OLP) is a T cell-mediated chronic inflammatory disorder with multifactorial aetiology and malignant transformation potential. Despite the treatments so far identified, new tailored and safe specific measures are needed. Recently, human microbiota imbalance has been linked to several immune-mediated diseases, opening new therapeutic perspectives for probiotics; besides their ability to directly interact with the host microbiota, they also display a strain-specific immune-modulatory effect. Thus, this non-systematic review aims to elucidate the molecular pathways underlying probiotic activity, mainly those of Lactobacilli and Bifidobacteria and their metabolites in OLP pathogenesis and malignant transformation, focusing on the most recent in vitro and in vivo research evidence. Findings related to their activity in other immune-mediated diseases are here included, suggesting a probiotic translational use in OLP. Probiotics show immune-modulatory and microbiota-balancing activities; they protect the host from pathogens, hamper an excessive effector T cell response, reduce nuclear factor-kappa B (NF-kB) signalling and basal keratinocytes abnormal apoptosis, shifting the mucosal response towards the production of anti-inflammatory cytokines, thus preventing uncontrolled damage. Therefore, probiotics could be a highly encouraging prevention and immunotherapeutic approach for a safer and more sustainable OLP management.Entities:
Keywords: NF-kB signalling; T cells; apoptosis; cytokines; host-probiotic interaction; immune-modulatory activity; microbial metabolites; microbiota; oral lichen planus (OLP); probiotics
Mesh:
Substances:
Year: 2022 PMID: 35408849 PMCID: PMC8998608 DOI: 10.3390/ijms23073489
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Overview of altered signalling pathways in OLP disease. IFN = interferon; IL = interleukin; MAPK = mitogen-activated protein kinase; MMP = metalloproteinase; NET = neutrophil extracellular trap; NF-kB = nuclear factor-kappa B; OSCC = oral squamous cell carcinoma; STAT = signal transducer and activator of transcription; TIMP = tissue inhibitors of metalloproteinases; TGF = transforming growth factor; Th = T helper cells; TNF = tumour necrosis factor.
Figure 2Impact of probiotics on inflammatory and apoptotic pathways and T cell population regulation. For each pathway, probiotics that display a regulatory effect are listed in the coloured boxes (upper part) and linked with the diseases in which this effect was observed (lower part), as evidenced by the circles with the same colour. AT = atopic dermatitis; BC = breast cancer; CP = chronic periodontitis; CRC = colorectal cancer; EAE = experimental autoimmune encephalomyelitis; GC = gastric cancer; IBD = inflammatory bowel disease; LPS = lipopolysaccharide; MG = myasthenia gravis; MMP = metalloproteinase; MS = multiple sclerosis; NAFLD = non-alcoholic fatty liver disease; ND = neurodegenerative disease; NOD = non-obese diabetic mouse; OA = osteoarthritis; OCC = oral cancer cells; OLP = oral lichen planus; OM = oral mucositis; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; TIMP = tissue inhibitors of metalloproteinases.